The compound you described, **[2-(1-piperidinyl)-1,3-benzothiazol-6-yl]-[4-(2-pyridinyl)-1-piperazinyl]methanone**, is a chemical entity with a complex structure. While I can't provide specific details about its research importance without more context, I can give you a general idea of why such compounds are studied:
**1. Potential for Drug Discovery:**
* **Diverse Structure:** The compound combines features from different chemical classes (benzothiazole, piperidine, piperazine, pyridine), suggesting it could interact with a range of biological targets.
* **Potential Pharmacological Activities:** The presence of these structural elements often points to potential activities like:
* **Antimicrobial:** Benzothiazole derivatives are known for their antibacterial and antifungal properties.
* **Anti-inflammatory:** Piperidine and piperazine rings can influence the activity of inflammatory pathways.
* **Neuroactive:** The pyridine moiety is frequently found in compounds that interact with the nervous system.
**2. Understanding Biological Processes:**
* **Structure-Activity Relationship:** Researchers study how the structure of such compounds affects their activity. This helps understand how molecules interact with biological systems.
* **Target Validation:** Investigating the effects of this compound on specific biological targets can help researchers confirm the importance of those targets in disease processes.
**3. Chemical Synthesis and Development:**
* **New Synthetic Methods:** Creating complex molecules like this often requires developing novel chemical synthesis methods.
* **Chemical Diversity:** This compound could serve as a starting point for developing new derivatives with potentially improved activity or properties.
**To find out more about the specific importance of [2-(1-piperidinyl)-1,3-benzothiazol-6-yl]-[4-(2-pyridinyl)-1-piperazinyl]methanone, you would need to:**
* **Search for publications:** Use scientific databases (PubMed, Scopus, Web of Science) to look for research articles that mention this compound.
* **Check patent databases:** Patents can indicate its potential use in pharmaceuticals or other applications.
* **Contact researchers in the field:** Connect with scientists working on drug discovery or medicinal chemistry to learn about their current research.
Remember that **without more information about the specific research context, it's difficult to give definitive answers** about the importance of this compound.
ID Source | ID |
---|---|
PubMed CID | 5308255 |
CHEMBL ID | 1610344 |
CHEBI ID | 105670 |
Synonym |
---|
MLS001367471 |
smr000096636 |
MLS000119715 , |
CHEBI:105670 |
AKOS001860376 |
(2-piperidino-1,3-benzothiazol-6-yl)[4-(2-pyridyl)piperazino]methanone |
(2-piperidin-1-yl-1,3-benzothiazol-6-yl)-(4-pyridin-2-ylpiperazin-1-yl)methanone |
HMS2248K23 |
cid_5308255 |
[2-(1-piperidinyl)-1,3-benzothiazol-6-yl]-[4-(2-pyridinyl)-1-piperazinyl]methanone |
(2-piperidino-1,3-benzothiazol-6-yl)-[4-(2-pyridyl)piperazino]methanone |
bdbm78032 |
CHEMBL1610344 |
HMS3446L02 |
Q27183427 |
Class | Description |
---|---|
piperazines | |
pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 10.0000 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 11.2202 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.3564 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
USP1 protein, partial | Homo sapiens (human) | Potency | 0.8913 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 10.0000 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 56.2341 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 1.4125 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | IC50 (µMol) | 46.1000 | 0.5800 | 26.5476 | 75.8000 | AID493003 |
Monoglyceride lipase | Homo sapiens (human) | IC50 (µMol) | 33.3000 | 0.0009 | 1.1268 | 10.0000 | AID1759076 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
lysophospholipase activity | Monoglyceride lipase | Homo sapiens (human) |
protein binding | Monoglyceride lipase | Homo sapiens (human) |
protein homodimerization activity | Monoglyceride lipase | Homo sapiens (human) |
acylglycerol lipase activity | Monoglyceride lipase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
endoplasmic reticulum membrane | Monoglyceride lipase | Homo sapiens (human) |
cytosol | Monoglyceride lipase | Homo sapiens (human) |
plasma membrane | Monoglyceride lipase | Homo sapiens (human) |
membrane | Monoglyceride lipase | Homo sapiens (human) |
membrane | Monoglyceride lipase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1759076 | Inhibition of MAGL (unknown origin) | 2021 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 41 | Discovery of novel reversible monoacylglycerol lipase inhibitors via docking-based virtual screening. |
AID1759079 | Inhibition of MAGL (unknown origin) at 33.33 uM relative to control | 2021 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 41 | Discovery of novel reversible monoacylglycerol lipase inhibitors via docking-based virtual screening. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |